Elsevier

The Lancet

Volume 367, Issue 9517, 8–14 April 2006, Pages 1173-1180
The Lancet

Articles
Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

https://doi.org/10.1016/S0140-6736(06)68507-3Get rights and content

Summary

Background

BCG vaccine has shown consistently high efficacy against childhood tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases. We assess and compare the costs and effects of BCG as an intervention against severe childhood tuberculosis in different regions of the world.

Methods

We calculated the number of tuberculous meningitis and miliary tuberculosis cases that have been and will be prevented in all children born in 2002, by combining estimates of the annual risk of tuberculosis infection, the proportion of infections that lead to either of these diseases in unvaccinated children, the number of children vaccinated, and BCG efficacy.

Findings

We estimated that the 100·5 million BCG vaccinations given to infants in 2002 will have prevented 29 729 cases of tuberculous meningitis (5th–95th centiles, 24 063–36 192) in children during their first 5 years of life, or one case for every 3435 vaccinations (2771–4177), and 11 486 cases of miliary tuberculosis (7304–16 280), or one case for every 9314 vaccinations (6172–13 729). The numbers of cases prevented would be highest in South East Asia (46%), sub-Saharan Africa (27%), the western Pacific region (15%), and where the risk of tuberculosis infection and vaccine coverage are also highest. At US$2–3 per dose, BCG vaccination costs US$206 (150–272) per year of healthy life gained.

Interpretation

BCG vaccination is a highly cost-effective intervention against severe childhood tuberculosis; it should be retained in high-incidence countries as a strategy to supplement the chemotherapy of active tuberculosis.

Introduction

Randomised controlled trials and case-control studies have shown consistently high efficacy of BCG vaccination against severe forms of childhood tuberculosis, principally miliary disease and meningitis, but variable efficacy against pulmonary tuberculosis in adults.1, 2, 3, 4, 5 Increases in tuberculous meningitis and mycobacterial glandular disease were reported after BCG vaccination was discontinued in Sweden and the former Czechoslovakia.6, 7, 8 BCG also prevents leprosy.9 More controversially, it might reduce childhood mortality from other causes, perhaps because BCG promotes a T-helper-1 immune response.10, 11 The studies whose results showed high efficacy against severe childhood tuberculosis have lent support to the view that BCG should continue to be used in countries where the disease remains a substantial public-health problem, and roughly 100 million doses are given to infants every year.

However, the evidence for efficacy from trials is not, on its own, sufficient to justify BCG vaccination on its present large scale. That argument needs an assessment of the number of cases and deaths prevented in relation to effort and cost. We have used information about efficacy together with data for risk of severe childhood tuberculosis to assess, for all countries and territories where BCG vaccine is routinely administered to infants, the number of cases of tuberculous meningitis and miliary tuberculosis expected, with and without BCG vaccination, in children born in 2002. This analysis leads to estimates of the numbers of cases prevented by country, by region, and for the whole world.

Section snippets

Methods

We assessed the annual risk of infection for tuberculosis by country and the risk of tuberculous meningitis and miliary tuberculosis in children after infection, and we have updated earlier meta-analyses of BCG efficacy. To see whether BCG vaccination is good value for money in comparison with other health programmes, we have calculated the cost of vaccination per case and death prevented, and the cost per year of healthy life gained.

Results

According to the methods described, the BCG vaccinations given to 100·5 million of the 132·8 million children born in 2002 would have prevented almost 30 000 cases of tuberculous meningitis, or one case for roughly every 3500 inoculations (table 4). These vaccinations will also have prevented nearly 11 500 cases of miliary tuberculosis, or one case for roughly every 9300 inoculations. Most of the cases would have been prevented in southeast Asia (46%), Africa (27%, both African regions

Discussion

The 100 million doses of BCG vaccine given to children every year prevent about 40 000 cases of tuberculous meningitis and miliary tuberculosis before these children reach their fifth birthdays, or roughly one case prevented for every 2500 inoculations. Worldwide, the cost of vaccination is US$200 or less per year of healthy life gained. The cost per DALY gained in every region of the world is much less than the average annual income per head (eg, gross national income ⩽US$735 in low income

References (74)

  • K Murtagh

    Efficacy of BCG

    Lancet

    (1980)
  • HN Barnum

    Cost savings from alternative treatments for tuberculosis

    Soc Sci Med

    (1986)
  • VS Pathania et al.

    A cost-benefit analysis of BCG revaccination in the Czech Republic

    Vaccine

    (1999)
  • AM Garber et al.

    Economic foundations of cost-effectiveness analysis

    J Health Econ

    (1997)
  • CJL Murray et al.

    Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries

    Lancet

    (1991)
  • ML Garly et al.

    BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?

    Vaccine

    (2003)
  • LC Rodrigues et al.

    Protective effect of BCG against TB meningitis and miliary TB: a meta-analysis

    Int J Epidemiol

    (1993)
  • GA Colditz et al.

    Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

    JAMA

    (1994)
  • PEM Fine

    BCG vaccines and vaccination

  • GA Colditz et al.

    The efficacy of Bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature

    Pediatrics

    (1995)
  • A Roth et al.

    Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau

    Pediatr Infect Dis J

    (2004)
  • PEM Fine et al.
  • World population prospects: the 2002 Revision

    (2002)
  • National tuberculosis prevalence survey, 2002, Cambodia

    (2005)
  • C Dye et al.

    Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country

    JAMA

    (1999)
  • EL Corbett et al.

    The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

    Arch Intern Med

    (2003)
  • K Styblo

    The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis

    Bull Int Union Tuberc Lung Dis

    (1985)
  • K Styblo
  • N Yamada et al.
  • Nationwide random survey for the epidemiology of tuberculosis in 1990

    (1990)
  • Report on Nationwide Random Survey for the Epidemiology of Tuberculosis in 2000

    (2000)
  • TE Tupasi et al.

    The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines

    Int J Tuberc Lung Dis

    (1999)
  • TE Tupasi et al.

    BCG coverage and the annual risk of tuberculosis infection over a 14-year period in the Philippines assessed from the Nationwide Prevalence Surveys

    Int J Tuberc Lung Dis

    (2000)
  • YP Hong et al.

    The seventh nationwide tuberculosis prevalence survey in Korea, 1995

    Int J Tuberc Lung Dis

    (1998)
  • JA Odhiambo et al.

    Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986–1996

    Am J Public Health

    (1999)
  • Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983–1998

    Int J Tuberc Lung Dis

    (2001)
  • Cited by (869)

    • BCG centenary: Lessons learnt

      2023, Indian Journal of Tuberculosis
    View all citing articles on Scopus
    View full text